Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide in Chronic Hepatitis D
NCT07309380Phase 3Not yet recruiting
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Jun 2027
- Primary completion
- Jun 2028
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of hepalatide in chronic hepatitis D, sponsored by Shanghai Hepu Pharmaceutical. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
hepalatide
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07309380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309380.